Key result
Adding cardiorenal biomarkers to clinical models improves LVH detection in CKD to AUC ~0.81.
Why the study?
Asymptomatic LVH is often missed in routine screening of CKD patients, and whether a biomarker-enhanced model improves detection of prevalent LVH in non-dialysis CKD remained unclear.
Does a cardiorenal biomarker-enhanced model incorporating UACR, NT-proBNP, and sST2 improve the detection of prevalent left ventricular hypertrophy compared to a clinical model alone in non-dialysis patients with chronic kidney disease?
Cross-Sectional (n=647)
Does a cardiorenal biomarker-enhanced model incorporating UACR, NT-proBNP, and sST2 improve the detection of prevalent left ventricular hypertrophy compared to a clinical model alone in non-dialysis patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
A cardiorenal biomarker-enhanced model incorporating UACR, NT-proBNP, and sST2 improves discrimination for prevalent LVH in non-dialysis CKD patients, potentially helping to prioritize echocardiography referrals for asymptomatic individuals.
Left ventricular hypertrophy (LVH) acts as a key factor for determinant of adverse cardiovascular outcomes in patients with chronic kidney disease (CKD). Echocardiography is the standard method for LVH assessment. Yet asymptomatic LVH patients are often overlooked or missed in routine screening. Whether a biomarker-enhanced model improves detection of prevalent LVH in non-dialysis CKD remains unclear. This cross-sectional study included 647 non-dialysis patients with CKD. We developed a clinical model based on female, age, body mass index, systolic blood pressure, hypertension, cardiovascular disease, estimated glomerular filtration rate, and serum phosphorus. Cardiorenal biomarkers, including urine albumin-to-creatinine ratio (UACR), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenicity 2 (sST2), were then added to assess their incremental value. Model performance was evaluated using discrimination, calibration, bootstrap internal validation, and decision curve analysis. LVH was present in 131 patients (20.2%). In multivariable analysis, female, hypertension, serum phosphorus, UACR, and sST2 were independently associated with LVH. NT‑proBNP was associated with LVH in univariable but not multivariable analysis. The clinical model had an AUC of 0.789. Adding three biomarkers improved the AUC to 0.812 (95% CI, 0.769–0.856), with lower Brier score and AIC. Bootstrap internal validation showed an optimism-corrected AUC of 0.790 and Brier score of 0.129. Decision curve analysis suggested higher net benefit for the biomarker-enhanced model across most threshold probabilities. A biomarker-enhanced model incorporating UACR, NT-proBNP, and sST2, have potential clinical applications to help prioritize echocardiography referrals for asymptomatic CKD patients who may have prevalent LVH.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) conducted a cross-sectional in Non-dialysis chronic kidney disease (CKD) with prevalent left ventricular hypertrophy (LVH) (n=647). Cardiorenal biomarker-enhanced model (adding UACR, NT-proBNP, and sST2 to a clinical model) vs. Clinical model alone (female sex, age, BMI, systolic blood pressure, hypertension, cardiovascular disease, eGFR, and serum phosphorus) was evaluated on Detection of prevalent left ventricular hypertrophy (LVH) (AUC 0.812, 95% CI 0.769-0.856). Adding cardiorenal biomarkers (UACR, NT-proBNP, sST2) to a clinical model improved detection of prevalent LVH in non-dialysis CKD from AUC 0.789 to 0.812.
Synapse has enriched 10 related papers. Consider them for comparative context: